...A. Highlights: As it begin this year, Co. is building on the significant momentum from the key successes achieved in 2022, highlighted by its progress in advancing 3D near-term commercial opportunities towards the market. 1. 2. With eplontersen, Co. delivered positive data from the 35 week interim analysis, which form the basis for Co.'s NDA submission in Dec. 3. With olezarsen, Co. completed enrollment in the Phase 3 balanced study for FCS, putting it on-track for data in 2H23. FDA recently granted Fast Track designation for olezarsen for SCS, underscoring the significant unmet medical need for these patients. a. b. Advanced and expanded clinical program supporting olezarsen for the broader SHTG indication. 4. With donidalorsen, Co. delivered multiple positive data readouts, all further strengthening its belief in this medicine's potential best-in-class profile for the prophylactic treatment of HAE. 5. Phase 3 study of donidalorsen continues to progress well, keeping Co. on-track to complete...
